Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 56 results
[
Author
]
Title
Type
Year
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
B
Badros AZ
,
Vij R
,
Martin T
,
Zonder JA
,
Kunkel L
,
Wang Z
,
Lee S
,
Wong AF
,
Niesvizky R
. 2013.
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
.
Leukemia. 27(8):1707-14.
Boussi L
,
Niesvizky R
. 2017.
Advances in immunotherapy in multiple myeloma.
.
Curr Opin Oncol. 29(6):460-466.
Braunstein M
,
Niesvizky R
. 2016.
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.
.
Semin Oncol. 43(6):709-711.
C
Castillo JJ
,
Jurczyszyn A
,
Brozova L
,
Crusoe E
,
Czepiel J
,
Davila J
,
Dispenzieri A
,
Eveillard M
,
Fiala MA
,
Ghobrial IM
et al.
. 2017.
IgM myeloma: A multicenter retrospective study of 134 patients.
.
Am J Hematol. 92(8):746-751.
D
Dimopoulos MA
,
Stewart AK
,
Masszi T
,
Špička I
,
Oriol A
,
Hájek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
.
Blood Cancer J. 7(4):e554.
Dimopoulos MA
,
Terpos E
,
Niesvizky R
. 2013.
How lenalidomide is changing the treatment of patients with multiple myeloma.
.
Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.
Dimopoulos MA
,
A Stewart K
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
.
Br J Haematol. 177(3):404-413.
Dimopoulos MA
,
Terpos E
,
Niesvizky R
,
Palumbo A
. 2015.
Clinical characteristics of patients with relapsed multiple myeloma.
.
Cancer Treat Rev. 41(10):827-35.
Dimopoulos MA
,
Goldschmidt H
,
Niesvizky R
,
Joshua D
,
Chng W-J
,
Oriol A
,
Orlowski RZ
,
Ludwig H
,
Facon T
,
Hajek R
et al.
. 2017.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
.
Lancet Oncol. 18(10):1327-1337.
E
Ely S
,
Forsberg P
,
Ouansafi I
,
Rossi A
,
Modin A
,
Pearse R
,
Pekle K
,
Perry A
,
Coleman M
,
Jayabalan D
et al.
. 2017.
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
.
Clin Lymphoma Myeloma Leuk. 17(12):825-833.
G
Gay F
,
S Rajkumar V
,
Coleman M
,
Kumar S
,
Mark T
,
Dispenzieri A
,
Pearse R
,
Gertz MA
,
Leonard J
,
Lacy MQ
et al.
. 2010.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
.
Am J Hematol. 85(9):664-9.
Geyer JT
,
Niesvizky R
,
Jayabalan DS
,
Mathew S
,
Subramaniyam S
,
Geyer AI
,
Orazi A
,
Ely SA
. 2014.
IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.
.
Mod Pathol. 27(3):375-81.
Goldschmidt H
,
Moreau P
,
Ludwig H
,
Niesvizky R
,
Chng W-J
,
Joshua D
,
Weisel K
,
Spencer A
,
Orlowski RZ
,
Feng S
et al.
. 2018.
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
.
Leuk Lymphoma. 59(6):1364-1374.
J
Jhaveri KD
,
Niesvizky R
. 2017.
High-Cutoff Hemodialysis in Myeloma Cast Nephropathy.
.
JAMA. 318(21):2085-2086.
Jurczyszyn A
,
Nahi H
,
Avivi I
,
Gozzetti A
,
Niesvizky R
,
Yadlapati S
,
Jayabalan DS
,
Robak P
,
Pika T
,
Andersen KT
et al.
. 2016.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
.
Br J Haematol. 175(5):884-891.
K
Kaufman JL
,
Niesvizky R
,
Stadtmauer EA
,
Chanan-Khan A
,
Siegel D
,
Horne H
,
Wegener WA
,
Goldenberg DM
. 2013.
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
.
Br J Haematol. 163(4):478-86.
Krishnan U
,
Mark TM
,
Niesvizky R
,
Sobol I
. 2015.
Pulmonary hypertension complicating multiple myeloma.
.
Pulm Circ. 5(3):590-7.
Kumar SK
,
Bensinger WI
,
Zimmerman TM
,
Reeder CB
,
Berenson JR
,
Berg D
,
Hui A-M
,
Gupta N
,
Di Bacco A
,
Yu J
et al.
. 2014.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
.
Blood. 124(7):1047-55.
Kumar SK
,
Berdeja JG
,
Niesvizky R
,
Lonial S
,
Laubach JP
,
Hamadani M
,
A Stewart K
,
Hari P
,
Roy V
,
Vescio R
et al.
. 2014.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
.
Lancet Oncol. 15(13):1503-12.
Kwon D
,
Niesvizky R
. 2013.
Treatment of multiple myeloma with carfilzomib in patients with renal injury.
.
Clin Adv Hematol Oncol. 11(9):605-6.
L
Ludwig H
,
Dimopoulos MA
,
Moreau P
,
Chng W-J
,
Goldschmidt H
,
Hajek R
,
Facon T
,
Pour L
,
Niesvizky R
,
Oriol A
et al.
. 2017.
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
.
Leuk Lymphoma. 58(10):2501-2504.
M
Mark TM
,
Reid W
,
Niesvizky R
,
Gergis U
,
Pearse R
,
Mayer S
,
Greenberg J
,
Coleman M
,
van Besien K
,
Shore T
. 2013.
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
.
Biol Blood Marrow Transplant. 19(5):831-7.
Mark T
,
Stern J
,
Furst JR
,
Jayabalan D
,
Zafar F
,
Larow A
,
Pearse RN
,
Harpel J
,
Shore T
,
Schuster MW
et al.
. 2008.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
.
Biol Blood Marrow Transplant. 14(7):795-8.
Mark TM
,
Bowman IA
,
Rossi AC
,
Shah M
,
Rodriguez M
,
Quinn R
,
Pearse RN
,
Zafar F
,
Pekle K
,
Jayabalan D
et al.
. 2014.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
.
Leuk Lymphoma. 55(12):2842-9.
1
(current)
2
3
next ›
last »